Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN   US75886F1075

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/27/2014 10/28/2014 10/29/2014 10/30/2014 10/31/2014 Date
407.16(c) 397.89(c) 387.7(c) 392.8(c) 393.72(c) Last
559 895 1 028 670 1 056 233 709 185 651 133 Volume
+1.16% -2.28% -2.56% +1.32% +0.23% Change
More quotes
Company
Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company.It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.Regeneron markets medicines for eye diseases, colorectal cancer and a rare inflammatory condition and... 
Sector
Pharmaceuticals
Calendar
11/04Earnings Release
Surperformance© rating of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More about the company
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 2 806 M
EBIT 2014 1 125 M
Net income 2014 425 M
Finance 2014 1 076 M
Yield 2014 -
Sales 2015 3 500 M
EBIT 2015 1 557 M
Net income 2015 795 M
Finance 2015 2 292 M
Yield 2015 -
PER 2014 106,55
PER 2015 59,37
EV / Sales 2014 13,8x
EV / Sales 2015 10,7x
Capitalization 39 792 M
More Financials
Latest news on REGENERON PHARMACEUTICALS
2d agoREGENERON PHARMACEUTICALS INC : quaterly earnings release
2d ago REGENERON PHARMACEUTICALS : Assigned Patent
3d ago REGENERON PHARMACEUTICALS : and Sanofi Announce Start of Phase 3 Study of Dupilu..
6d ago REGENERON PHARMACEUTICALS : Earns Top Spot as Employer in the Global Biopharmace..
10/23 REGENERON PHARMACEUTICALS : Assigned Patent
10/22 REGENERON PHARMACEUTICALS : Ranked Number One Biopharmaceutical Employer by Scie..
10/22 REGENERON PHARMACEUTICALS : Reports on Vaccines from Regeneron Pharmaceuticals I..
10/22 REGENERON PHARMACEUTICALS : EYLEA® aflibercept Injection Demonstrates Significan..
10/21 SANOFI : and Regeneron Announce Start of Phase 3 Study of Dupilumab in Patients ..
10/21 REGENERON PHARMACEUTICALS : Earns Top Spot as Employer in the Global Biopharmace..
10/20 REGENERON PHARMACEUTICALS : and Sanofi Announce Start of Phase 3 Study of Dupilu..
10/19 REGENERON PHARMACEUTICALS : FDA OKs Eylea (aflibercept) Injection
More news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF